1 false false false false false false false false false false true false false false false false false No description of principal activity 2024-04-01 Sage Accounts Production Advanced 2024 - FRS102_2024 8,000 8,000 290 100 190 190 290 xbrli:pure xbrli:shares iso4217:GBP SC280040 2024-04-01 2025-03-31 SC280040 2025-03-31 SC280040 2024-03-31 SC280040 2023-04-01 2024-03-31 SC280040 2024-03-31 SC280040 2023-03-31 SC280040 core:NetGoodwill 2024-04-01 2025-03-31 SC280040 core:PlantMachinery 2024-04-01 2025-03-31 SC280040 core:FurnitureFittings 2024-04-01 2025-03-31 SC280040 core:MotorVehicles 2024-04-01 2025-03-31 SC280040 bus:Director1 2024-04-01 2025-03-31 SC280040 core:NetGoodwill 2025-03-31 SC280040 core:LandBuildings 2024-03-31 SC280040 core:PlantMachinery 2024-03-31 SC280040 core:FurnitureFittings 2024-03-31 SC280040 core:MotorVehicles 2024-03-31 SC280040 core:LandBuildings 2025-03-31 SC280040 core:PlantMachinery 2025-03-31 SC280040 core:FurnitureFittings 2025-03-31 SC280040 core:MotorVehicles 2025-03-31 SC280040 core:LandBuildings 2024-04-01 2025-03-31 SC280040 core:WithinOneYear 2025-03-31 SC280040 core:WithinOneYear 2024-03-31 SC280040 core:ShareCapital 2025-03-31 SC280040 core:ShareCapital 2024-03-31 SC280040 core:RetainedEarningsAccumulatedLosses 2025-03-31 SC280040 core:RetainedEarningsAccumulatedLosses 2024-03-31 SC280040 core:CostValuation core:Non-currentFinancialInstruments 2024-03-31 SC280040 core:DisposalsRepaymentsInvestments core:Non-currentFinancialInstruments 2025-03-31 SC280040 core:CostValuation core:Non-currentFinancialInstruments 2025-03-31 SC280040 core:Non-currentFinancialInstruments 2025-03-31 SC280040 core:Non-currentFinancialInstruments 2024-03-31 SC280040 core:LandBuildings 2024-03-31 SC280040 core:PlantMachinery 2024-03-31 SC280040 core:FurnitureFittings 2024-03-31 SC280040 core:MotorVehicles 2024-03-31 SC280040 bus:SmallEntities 2024-04-01 2025-03-31 SC280040 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 SC280040 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 SC280040 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 SC280040 bus:FullAccounts 2024-04-01 2025-03-31 SC280040 core:Subsidiary1 2024-04-01 2025-03-31 SC280040 core:Subsidiary1 2023-04-01 2024-03-31 SC280040 core:Subsidiary2 2024-04-01 2025-03-31 SC280040 core:Subsidiary2 2023-04-01 2024-03-31 SC280040 core:Subsidiary3 2024-04-01 2025-03-31 SC280040 core:Subsidiary3 2023-04-01 2024-03-31 SC280040 core:OfficeEquipment 2024-04-01 2025-03-31 SC280040 core:OfficeEquipment 2024-03-31 SC280040 core:OfficeEquipment 2025-03-31
COMPANY REGISTRATION NUMBER: SC280040

KJW Clinical Research Limited

Filleted Unaudited Financial Statements

For the year ended

31 March 2025

KJW Clinical Research Limited

Statement of Financial Position

31 March 2025

| 2025 | 2024
Note | £ | £

Fixed assets

Tangible assets | 6 | 196,076 | 303,293
Investments | 7 | 190 | 290
| --------- | ---------
| 196,266 | 303,583

Current assets

Debtors | 8 | 3,810 | 3,827
Cash at bank and in hand | 518,378 | 356,085
| --------- | ---------
| 522,188 | 359,912

Creditors: amounts falling due within one year | 9 | 58,592 | 63,057
| --------- | ---------
Net current assets | 463,596 | 296,855
| --------- | ---------
Total assets less current liabilities | 659,862 | 600,438
| --------- | ---------
Net assets | 659,862 | 600,438
| --------- | ---------

Capital and reserves

Called up share capital | 1 | 1
Profit and loss account | 659,861 | 600,437
| --------- | ---------
Shareholder funds | 659,862 | 600,438
| --------- | ---------

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .

KJW Clinical Research Limited

Statement of Financial Position (continued)

31 March 2025
These financial statements were approved by the board of directors and authorised for issue on 28 October 2025 , and are signed on behalf of the board by:

Dr K J Williams |
Director |

Company registration number: SC280040

KJW Clinical Research Limited

Notes to the Financial Statements

Year ended 31 March 2025
1. General information
The company is a private company limited by shares, registered in Scotland. The address of the registered office is 33 Kittoch Street, East Kilbride, Glasgow, G74 4JW.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Consolidation
The company has taken advantage of the option not to prepare consolidated financial statements contained in Section 398 of the Companies Act 2006 on the basis that the company and its subsidiary undertakings comprise a small group.
Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Income tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Amortisation
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:

| Goodwill | - | 20% straight line

If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.
Tangible assets
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

| Library | - | 20% reducing balance
| Fixtures and fittings | - | 15% reducing balance
| Motor vehicles | - | 25% reducing balance
| Equipment | - | 25% reducing balance

Investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.
Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Investments in associates
Investments in associates accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in associates accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the associate arising before or after the date of acquisition.
Investments in joint ventures
Investments in jointly controlled entities accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in jointly controlled entities accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the joint venture arising before or after the date of acquisition.
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Defined contribution plans
Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund. When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised as a finance cost in profit or loss in the period in which it arises.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 1 (2024: 1 ).
5. Intangible assets

| Goodwill
| £
Cost |
At 1 April 2024 and 31 March 2025 | 8,000
| -------
Amortisation |
At 1 April 2024 and 31 March 2025 | 8,000
| -------
Carrying amount |
At 31 March 2025 | –
| -------
At 31 March 2024 | –
| -------

6. Tangible assets

| Land and buildings | Library | Fixtures and fittings | Motor vehicles | Equipment | Total
| £ | £ | £ | £ | £ | £
Cost |  |  |  |  |  |
At 1 Apr 2024 | 291,155 | 6,816 | 52,713 | 25,037 | 2,327 | 378,048
Additions | – | – | – | 32,630 | – | 32,630
Disposals | ( 126,070) | – | – | ( 25,037) | – | ( 151,107)
| --------- | ------- | -------- | -------- | ------- | ---------
At 31 Mar 2025 | 165,085 | 6,816 | 52,713 | 32,630 | 2,327 | 259,571
| --------- | ------- | -------- | -------- | ------- | ---------
Depreciation |  |  |  |  |  |
At 1 Apr 2024 | – | 6,691 | 45,191 | 20,581 | 2,292 | 74,755
Charge for the year | – | 25 | 1,129 | 8,158 | 9 | 9,321
Disposals | – | – | – | ( 20,581) | – | ( 20,581)
| --------- | ------- | -------- | -------- | ------- | ---------
At 31 Mar 2025 | – | 6,716 | 46,320 | 8,158 | 2,301 | 63,495
| --------- | ------- | -------- | -------- | ------- | ---------
Carrying amount |  |  |  |  |  |
At 31 Mar 2025 | 165,085 | 100 | 6,393 | 24,472 | 26 | 196,076
| --------- | ------- | -------- | -------- | ------- | ---------
At 31 Mar 2024 | 291,155 | 125 | 7,522 | 4,456 | 35 | 303,293
| --------- | ------- | -------- | -------- | ------- | ---------

7. Investments

| Shares in group undertakings
| £
Cost |
At 1 April 2024 | 290
Disposals | ( 100)
| ----
At 31 March 2025 | 190
| ----
Impairment |
At 1 April 2024 and 31 March 2025 | –
| ----

Carrying amount |
At 31 March 2025 | 190
| ----
At 31 March 2024 | 290
| ----

8. Debtors

| 2025 | 2024
| £ | £
Other debtors | 3,810 | 3,827
| ------- | -------

9. Creditors: amounts falling due within one year

| 2025 | 2024
| £ | £
Corporation tax | 6,923 | 11,412
Other creditors | 51,669 | 51,645
| -------- | --------
| 58,592 | 63,057
| -------- | --------

10. Related party transactions
During the year the company entered into the following transactions with related parties:

| Transaction value
| 2025 | 2024
| £ | £
Karma Oncology Limited | 170,000 | 159,200
Karma Cardiology Limited | – | 9,298
Karma Oncology BV Ltd | 87,000 | 37,000
| --------- | ---------

Control:- The company was under the control of Dr K J Williams throughout the current and previous year. Dr K J Williams is the sole director and shareholder. Transactions:- During the year the company provided management services amounting to £120,000 (2024:£102,200) to Karma Oncology Limited, a wholly owned subsidiary company incorporated in Scotland. During the year the company received dividends totalling £50,000 (2024: £57,000) from Karma Oncology Limited. During the year the company provided management services amounting to £87,000 (2023:£37,000) to Karma Oncology BV Limited, a wholly owned subsidiary company incorporated in the Netherlands.